AstriVax Therapeutics Company Profile, Contacts & Intelligence

AstriVax Therapeutics Overview

AstriVax Therapeutics is a European based, clinical-stage biopharmaceutical company, founded in 2022, that is pioneering immune interventions to treat chronic disease. The company has two prototype prophylactic assets in clinical phase and is developing its therapeutic assets to treat chronic HBV and clear high-risk HPV. AstriVax has a novel DNA-launched viral vector immunotherapy platform, Launch-iT, that is designed to create an inherent adjuvant effect to the target antigens, eliciting durable polyfunctional CD8+ and CD4+ T cell responses and robust humoral immunity. Through Launch-iT, the company has the potential to develop best-in-class immunotherapy treatments.

Headquarters

Heverlee, Vlaams Brabant, Be

Website

astrivax.com

Industry

Biotechnology Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology)

AstriVax Therapeutics Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

AstriVax Therapeutics People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

AstriVax Therapeutics Workforce Composition

Seniority breakdown across 4 visible profiles.

Compare Similar Companies to AstriVax Therapeutics

Explore companies in related markets and compare their industry and employee estimates.